BWA
TEVA icon

Basecamp Wealth Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Basecamp Wealth Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$983 Hold
29
– – ﹤0.01% 1526
2026
Q1 		$873 Hold
29
– – ﹤0.01% 1593
2025
Q4 		$905 Buy
+29
New +$714 ﹤0.01% 1520

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Basecamp Wealth Advisors's TEVA Position: Q2 2026 in Review

Basecamp Wealth Advisors held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 29 shares worth $983. The position accounts for ﹤0.01% of the portfolio, ranked #1526.

Basecamp Wealth Advisors first reported a position in TEVA in Q4 2025 and has held it in 3 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Basecamp Wealth Advisors held 29 shares of Teva Pharmaceuticals worth $983 as of Q2 2026.
  • Basecamp Wealth Advisors left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1526 holding.
  • Basecamp Wealth Advisors first reported a position in Teva Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.